This case study has been carried out by Carol Stonham MBE, a Medical Advisory Board member. Carol has worked as a registered nurse since 1986, shifting from acute hospital care to primary care by 1990 ...

Approximately 339 million people around the world are afflicted with asthma, with asthma-related mortality affecting the lives of three families each day. Staggeringly, around two-thirds of these ...

A meta-analysis shows that fractional exhaled nitrous oxide (FeNO) is a good evidence-based adjunct test for asthma A meta-analysis published in Mayo Clinic Proceedings shows that fractional exhaled ...

MORRISVILLE, N.C.--(BUSINESS WIRE)--Circassia Inc. announced today that it has successfully engaged with major primary care national sales partners to expand the distribution of NIOX VERO®, its FeNO ...

Aerocrine AB announced that Health Care Service Corp. will begin covering FeNO testing for asthma diagnosis and management effective April 1. According to a release, Aerocrine has received ...

BOSTON -- Is measuring fractional exhaled nitric oxide (FeNo), a way to measure airway inflammation, a useful biomarker that should be used in all asthma patients? Or is that nothing more than ...

Please provide your email address to receive an email when new articles are posted on . Fractional exhaled nitric oxide testing is beneficial and is recommended in addition to usual care in patients ...

IS LUNG HEALTH DAY, THOUGH MANY OF US TAKE BREATHING FOR GRANTED, MILLIONS OF PEOPLE STRUGGLE GETTING ENOUGH AIR DUE TO ASTHMA CONDITION THAT CAN BE DEADLY. AN ESTIMATED 262 MILLION PEOPLE WORLDWIDE ...

SOLNA, Sweden — Aerocrine AB, a medical products company focused on improved management and care of patients with such inflammatory airway diseases as asthma, has announced that a new randomized ...

SWEDEN — Aerocrine, a medical technology company with a focus on improving the treatment of patients with inflamed airways, announced that Health Care Services Corp. will begin covering fractional ...

SOLNA, Sweden--(BUSINESS WIRE)--Regulatory News: Aerocrine AB (STO:AERO-B) announces that Texas Medicaid will begin coverage of FeNO testing on April 1, 2013. The Texas Health and Human Services ...

Aerocrine AB announced that Health Care Service Corp. will begin covering FeNO testing for asthma diagnosis and management effective April 1. According to a release, Aerocrine has received ...